AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8446968 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (two doses)
Number of subjects: 2993
Study 3543037 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 injections of cefamandole (at induction of anesthesia and after 4 and 10 hours)
Number of subjects: 507
Study 3543037 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 injections of cefamandole (at induction of anesthesia, after 4 hours, then every 6 hours up to 40 hours)
Number of subjects: 507
Study 2900021 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical cerclage
Number of subjects: 905
Study 2900021 — intervention group
Group type: COMPARATOR
Intervention: No surgery
Number of subjects: 905
Study 29664800 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced recovery after surgery plus extended counseling (n = 80)
Number of subjects: 164
Study 29664800 — intervention group
Group type: COMPARATOR
Intervention: Enhanced recovery after surgery with standard counseling (n = 84)
Number of subjects: 164
Study 29664800 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (extended counseling and standard counseling)
Number of subjects: 164
Study 26419459 — intervention group
Group type: EXPERIMENTAL
Intervention: Purine analogues (PAs)
Number of subjects: 156
Study 26419459 — intervention group
Group type: COMPARATOR
Intervention: No purine analogues (PAs)
Number of subjects: 156
Study 26419459 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 156
Study 26419459 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 156
Study 25515692 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 mg of PSE in the morning (AM(PSE))
Number of subjects: 9
Study 25515692 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 mg of PSE in the afternoon (PM(PSE))
Number of subjects: 9
Study 25515692 — intervention group
Group type: COMPARATOR
Intervention: Placebo in the morning (AM(PLAC))
Number of subjects: 9
Study 25515692 — intervention group
Group type: COMPARATOR
Intervention: Placebo in the afternoon (PM(PLAC))
Number of subjects: 9
Study 25515692 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 mg of PSE
Number of subjects: 9
Study 23065316 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Workshop (IW)
Number of subjects: 203
Study 23065316 — intervention group
Group type: COMPARATOR
Intervention: Conventional Education (CE)
Number of subjects: 203
Study 20635521 — intervention group
Group type: EXPERIMENTAL
Intervention: Music training (n = 18)
Number of subjects: 50
Study 20635521 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech training (n = 18)
Number of subjects: 50
Study 20635521 — intervention group
Group type: COMPARATOR
Intervention: No training (Control, n = 14)
Number of subjects: 50
Study 18373989 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-body exercise program using an arm crank ergometer 3 times a week for 4 weeks
Number of subjects: 20
Study 18373989 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 20
Study 18373989 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-body exercise program
Number of subjects: 20
Study 18373989 — intervention group
Group type: COMPARATOR
Intervention: Both groups (training and control)
Number of subjects: 20
Study 16340195 — intervention group
Group type: COMPARATOR
Intervention: Topical acyclovir (ACV) ointment
Number of subjects: 28
Study 16340195 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral valacyclovir (VACV)
Number of subjects: 28
Study 15134308 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg GH/m2/day
Number of subjects: 79
Study 15134308 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg GH/m2/day
Number of subjects: 79
Study 15134308 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 79
Study 11561869 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme treatment (trypsin, chymotrypsin, and papain)
Number of subjects: 120
Study 9051139 — intervention group
Group type: COMPARATOR
Intervention: Granisetron (40 micrograms/kg) only
Number of subjects: 62
Study 9051139 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (40 micrograms/kg) plus steroids (500 mg of methylprednisolone or 8 mg of dexamethasone)
Number of subjects: 62
Study 8117868 — intervention group
Group type: EXPERIMENTAL
Intervention: Binifibrate
Number of subjects: 54
Study 8117868 — intervention group
Group type: COMPARATOR
Intervention: Gemfibrozil
Number of subjects: 54
Study 3511184 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral oophorectomy
Number of subjects: 53
Study 3511184 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (10 mg twice daily)
Number of subjects: 53
Study 3511184 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral oophorectomy (crossover treatment)
Number of subjects: 53
Study 3511184 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (crossover treatment)
Number of subjects: 53
Study 3511184 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral oophorectomy (visceral dominant subset)
Number of subjects: 53
Study 3511184 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (visceral dominant subset)
Number of subjects: 53
Study 3511184 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral oophorectomy (crossover in visceral dominant nonresponders)
Number of subjects: 53
Study 3511184 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to progression (initial treatment)
Number of subjects: 53
Study 3511184 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival rates
Number of subjects: 53
Study 31992444 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 305
Study 31992444 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy
Number of subjects: 305
Study 31992444 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative margin resection
Number of subjects: 305
Study 31992444 — intervention group
Group type: COMPARATOR
Intervention: Positive margin resection
Number of subjects: 305
Study 29882738 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy (LLLT) with a wavelength of 660 nm, 30 mW power, continuous mode emission, 6 J/cm2 dosimetry, applied every 48 hours for 4 weeks.
Number of subjects: 18
Study 29882738 — intervention group
Group type: COMPARATOR
Intervention: Control Group (no specific intervention details provided).
Number of subjects: 18
Study 27606275 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrective fusion surgery
Number of subjects: 47
Study 27606275 — intervention group
Group type: COMPARATOR
Intervention: Control group (N=44)
Number of subjects: 47
Study 24798786 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP measurement
Number of subjects: 177
Study 22669054 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezoelectric surgery (Group 2)
Number of subjects: 140
Study 22669054 — intervention group
Group type: COMPARATOR
Intervention: Conventional rotary instruments (Group 1)
Number of subjects: 140
Study 24576068 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of sulphadoxine-pyrimethamine (SP3)
Number of subjects: 1274
Study 24576068 — intervention group
Group type: COMPARATOR
Intervention: 2 doses of sulphadoxine-pyrimethamine (SP2)
Number of subjects: 1274
Study 18603751 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvenous, intracardial cardioversion (TIC) with ALERT pulmonary artery catheter
Number of subjects: 18
Study 18603751 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone treatment with standard pulmonary artery catheter
Number of subjects: 18
Study 15756217 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention program
Number of subjects: 15
Study 15756217 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 15
Study 12464202 — intervention group
Group type: EXPERIMENTAL
Intervention: Sternocleidomastoid flap
Number of subjects: 36
Study 10693099 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 0
Study 10693099 — intervention group
Group type: COMPARATOR
Intervention: Placebo (chlorothiazide)
Number of subjects: 0
Study 9352867 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 27
Study 9352867 — intervention group
Group type: EXPERIMENTAL
Intervention: ISMN
Number of subjects: 27
Study 9352867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 8450258 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 226
Study 8450258 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrimethamine/sulfadoxine
Number of subjects: 226
Study 3093214 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of carbamazepine (CBZ)
Number of subjects: 30
Study 3093214 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of phenytoin (PHT)
Number of subjects: 30
Study 3093214 — intervention group
Group type: EXPERIMENTAL
Intervention: Progabide (PGB)
Number of subjects: 30
Study 30950698 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretch‐and‐flow voice therapy (SnF)
Number of subjects: 21
Study 30950698 — intervention group
Group type: EXPERIMENTAL
Intervention: Resonant voice therapy (RVT)
Number of subjects: 21
Study 26321418 — intervention group
Group type: EXPERIMENTAL
Intervention: Test meal with variety (three different varieties of vegetables, meat or fish, and starch components)
Number of subjects: 19
Study 26321418 — intervention group
Group type: COMPARATOR
Intervention: Control meal without variety
Number of subjects: 19
Study 26321418 — intervention group
Group type: EXPERIMENTAL
Intervention: Test meal with variety
Number of subjects: 19
Study 23800482 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 294
Study 23800482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 294
Study 21558568 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided relaxation and exercise imagery (GREI) audio CD for 6 weeks
Number of subjects: 93
Study 21558568 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group with relaxation tracks and music for 6 weeks
Number of subjects: 93
Study 19453572 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural intervention (planning when, where and how to floss)
Number of subjects: 194
Study 19453572 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 194
Study 16919161 — intervention group
Group type: EXPERIMENTAL
Intervention: SFC (50/100 mcg)
Number of subjects: 108
Study 16919161 — intervention group
Group type: EXPERIMENTAL
Intervention: FBC (4.5/160 mcg)
Number of subjects: 108
Study 15327603 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous delivery (n=235)
Number of subjects: 472
Study 15327603 — intervention group
Group type: COMPARATOR
Intervention: Manual removal (n=237)
Number of subjects: 472
Study 11350283 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular-weight heparin
Number of subjects: 449
Study 11350283 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 449
Study 11350283 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperdense middle cerebral artery sign (HMCAS)
Number of subjects: 449
Study 9121987 — intervention group
Group type: EXPERIMENTAL
Intervention: PCD Jewel 7219C (14 patients)
Number of subjects: 51
Study 9121987 — intervention group
Group type: EXPERIMENTAL
Intervention: PCD Jewel 7219D (37 patients)
Number of subjects: 51
Study 9121987 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient group
Number of subjects: 51
Study 8202180 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 183
Study 8202180 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 183
Study 3428842 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyclothiazide 2 mg alone
Number of subjects: 8
Study 3428842 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyclothiazide 2 mg with triamterene 25 mg
Number of subjects: 8
Study 3428842 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyclothiazide 2 mg with larger doses of triamterene
Number of subjects: 8
Study 3428842 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 8
Study 31670388 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA methylations in UBE2L3 and BLK genes
Number of subjects: 0
Study 31670388 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA expression of UBE2L3
Number of subjects: 0
Study 31670388 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA expression of BLK
Number of subjects: 0
Study 31670388 — intervention group
Group type: EXPERIMENTAL
Intervention: plasma cathepsin B level
Number of subjects: 0
Study 31670388 — intervention group
Group type: EXPERIMENTAL
Intervention: UBE2L3 gene expression
Number of subjects: 0
Study 31670388 — intervention group
Group type: EXPERIMENTAL
Intervention: BLK single nucleotide polymorphisms
Number of subjects: 0
Study 30133775 — intervention group
Group type: EXPERIMENTAL
Intervention: Online mental health role‐play simulation (45-90 minutes)
Number of subjects: 18896
Study 28797238 — intervention group
Group type: EXPERIMENTAL
Intervention: Brace wearing for 6 weeks
Number of subjects: 126
Study 28797238 — intervention group
Group type: COMPARATOR
Intervention: No brace for 6 weeks
Number of subjects: 126
Study 25814467 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN‐α treatment
Number of subjects: 77
Study 23376601 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for treating child emotional and behavioral symptoms following trauma
Number of subjects: 0
Study 23376601 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal PTSD symptoms
Number of subjects: 0
Study 23376601 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced interventions targeting dyads with child PTSD symptoms and maternal depression or PTSD symptoms
Number of subjects: 0
Study 22087846 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy-intensity exercise (HIE) followed by moderate-intensity exercise (MIE) test 1, test 2, and test 3.
Number of subjects: 19
Study 18635446 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS (4 ng/kg body wt)
Number of subjects: 18
Study 18635446 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 18
Study 16826105 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-bearing tibial component
Number of subjects: 52
Study 16826105 — intervention group
Group type: COMPARATOR
Intervention: Fixed-bearing tibial component
Number of subjects: 52
Study 12821205 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer at 30 mg methadone
Number of subjects: 51
Study 12821205 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer when 'uncomfortable' dosing protocol
Number of subjects: 51
Study 12821205 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer from doses less than 30 mg methadone
Number of subjects: 51
Study 12821205 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine induction (first dose 4 mg)
Number of subjects: 51
Study 12821205 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 1 month
Number of subjects: 51
Study 12845731 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (1,000,000 KIU by vein injection and 2,000,000 KIU as a bolus in prime)
Number of subjects: 20
Study 12845731 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 20
Study 9308590 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA) in patients less than 50 years old
Number of subjects: 26
Study 9308590 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA) in patients greater than 55 years old (Control)
Number of subjects: 26
Study 7640544 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transdermal nicotine patches
Number of subjects: 629
Study 7640544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 629
Study 2565314 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate, 25 mg daily for 25 days with 5 days' rest each month
Number of subjects: 100
Study 2565314 — intervention group
Group type: COMPARATOR
Intervention: Ascorbic acid, 500 mg daily
Number of subjects: 100
Study 338090 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrotalcite
Number of subjects: 17
Study 338090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 31276502 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine patient support program (MSP)
Number of subjects: 93
Study 31276502 — intervention group
Group type: COMPARATOR
Intervention: Technical support only (Control)
Number of subjects: 93
Study 28495620 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (500mg/day) during pregnancy
Number of subjects: 450000
Study 28495620 — intervention group
Group type: COMPARATOR
Intervention: Placebo during pregnancy
Number of subjects: 450000
Study 26197451 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of AZD9056 administered orally as a tablet once daily for 28 days
Number of subjects: 34
Study 26197451 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 34
Study 25607793 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin barrier emulsion cream
Number of subjects: 0
Study 25607793 — intervention group
Group type: COMPARATOR
Intervention: Conventional moisturizer
Number of subjects: 0
Study 22343536 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieved SBP between 131 and 141 mmHg
Number of subjects: 9193
Study 22343536 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieved SBP 130 mmHg or less
Number of subjects: 9193
Study 22343536 — intervention group
Group type: COMPARATOR
Intervention: Achieved SBP at least 142 mmHg
Number of subjects: 9193
Study 19207770 — intervention group
Group type: EXPERIMENTAL
Intervention: Double linear endocardial ablation of left lateral isthmus (LLI) along the vein of Marshall (VOM)
Number of subjects: 54
Study 19207770 — intervention group
Group type: COMPARATOR
Intervention: No LLI block (control group)
Number of subjects: 54
Study 17577006 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 11
Study 16294458 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg 17beta‐E2/0.25 mg TMG
Number of subjects: 1218
Study 16294458 — intervention group
Group type: COMPARATOR
Intervention: 1 mg E2V/1 mg NET
Number of subjects: 1218
Study 11934964 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulphate 1500 mg daily for 6 months
Number of subjects: 80
Study 11934964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 9774808 — intervention group
Group type: EXPERIMENTAL
Intervention: Heme iron‐fortified cookies for 6‐8 weeks
Number of subjects: 108
Study 9774808 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fortification)
Number of subjects: 108
Study 8697383 — intervention group
Group type: EXPERIMENTAL
Intervention: Curative resection only
Number of subjects: 572
Study 1758415 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-absorbable membrane
Number of subjects: 0
Study 1758415 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable membrane
Number of subjects: 0
Study 7151087 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiapamil (1.1 mg/kg)
Number of subjects: 60
Study 7151087 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiapamil (1.6 mg/kg)
Number of subjects: 60
Study 7151087 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (0.07 mg/kg)
Number of subjects: 60
Study 7151087 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (0.14 mg/kg)
Number of subjects: 60
Study 7151087 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (placebo)
Number of subjects: 60
Study 7151087 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiapamil and Verapamil
Number of subjects: 60
Study 30850995 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 7637
Study 30850995 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine U100
Number of subjects: 7637
Study 28376899 — intervention group
Group type: EXPERIMENTAL
Intervention: Oats consumption (70 g of oats twice a day for 4 weeks)
Number of subjects: 80
Study 28376899 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (control group)
Number of subjects: 80
Study 25406260 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat/high-carbohydrate (HFHC) meal
Number of subjects: 10
Study 25406260 — intervention group
Group type: COMPARATOR
Intervention: American Heart Association (AHA) meal
Number of subjects: 10
Study 23813322 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) intervention consisting of 6 workshops on diabetes prevention, nutrition, physical activity, diabetes complications, stress and family support, and access to health care
Number of subjects: 48
Study 23813322 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 48
Study 21708042 — intervention group
Group type: EXPERIMENTAL
Intervention: HVLA‐SM (High-Velocity Low-Amplitude Spinal Manipulation)
Number of subjects: 219
Study 21708042 — intervention group
Group type: EXPERIMENTAL
Intervention: LVVA‐SM (Low-Velocity Variable-Amplitude Spinal Manipulation)
Number of subjects: 219
Study 21708042 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 219
Study 21708042 — intervention group
Group type: EXPERIMENTAL
Intervention: HVLA‐SM
Number of subjects: 219
Study 21708042 — intervention group
Group type: EXPERIMENTAL
Intervention: LVVA‐SM
Number of subjects: 219
Study 21708042 — intervention group
Group type: EXPERIMENTAL
Intervention: HVLA‐SM and LVVA‐SM
Number of subjects: 219
Study 19699875 — intervention group
Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide (BNP) measurement
Number of subjects: 452
Study 19699875 — intervention group
Group type: COMPARATOR
Intervention: Control (nonobese patients)
Number of subjects: 452
Study 16432472 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive addition lenses (PALs)
Number of subjects: 469
Study 16432472 — intervention group
Group type: COMPARATOR
Intervention: Single-vision lenses (SVLs)
Number of subjects: 469
Study 15540852 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 0
Study 15540852 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac
Number of subjects: 0
Study 11495219 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 1733